Trial Profile

A Phase 2 randomized, double-blind, parallel-group, placebo and active-controlled clinical study of Itolizumab in patients with Ulcerative Colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Feb 2025 According to an Equillium media release, the design and conduct of this study were a collaborative effort, with input from the gastroenterology community and leading global clinical and scientific experts in the field of inflammatory bowel disease (IBD).
06 Feb 2025 According to an Equillium media release, the company has announced positive topline results form this study and additional data from this study is expected to be presented at a future scientific conference during 2025.
06 Feb 2025 Results published in the Equillium Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com